E

Epsilogen Ltd

16 employees

Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Therapeutics
Genetics
Biopharma
Life Science

Date founded

2016

Funding rounds raised

Total raised

$41M

from 9 investors over 9 rounds

E

Epsilogen Ltd raised $41M on March 2, 2022

Investors: 3B Future Health Fund, British Patient Capital, Schroders Capital, Epidarex Capital and ALSA Ventures

E

Epsilogen Ltd raised $977K on April 2, 2019

Investors: Innovate UK

E

Epsilogen Ltd raised $6.4M on November 30, 2018

Investors: AlbionVC and Epidarex Capital

E

Epsilogen Ltd raised $2.5M on June 20, 2017

Investors: Epidarex Capital

FAQ